Both Nightstar Therapeutics plc (NASDAQ:NITE) and Checkpoint Therapeutics Inc. (NASDAQ:CKPT) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nightstar Therapeutics plc	N/A	0.00	42.26M	-1.93	0.00
Checkpoint Therapeutics Inc.	N/A	118.55	30.67M	-1.16	0.00

Table 1 demonstrates Nightstar Therapeutics plc and Checkpoint Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

	Net Margins	Return on Equity	Return on Assets
Nightstar Therapeutics plc	0.00%	-38.7%	-35.1%
Checkpoint Therapeutics Inc.	0.00%	-139%	-104.3%

Liquidity

Nightstar Therapeutics plc has a Current Ratio of 7.7 and a Quick Ratio of 7.7. Competitively, Checkpoint Therapeutics Inc.’s Current Ratio is 3.5 and has 3.5 Quick Ratio. Nightstar Therapeutics plc’s better ability to pay short and long-term obligations than Checkpoint Therapeutics Inc.

Institutional and Insider Ownership

Nightstar Therapeutics plc and Checkpoint Therapeutics Inc. has shares owned by institutional investors as follows: 49.8% and 11.8%. About 40.63% of Nightstar Therapeutics plc’s share are owned by insiders. Insiders Comparatively, owned 1.6% of Checkpoint Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Nightstar Therapeutics plc	-12.92%	23.65%	-46.32%	-7.57%	-23.12%	-0.38%
Checkpoint Therapeutics Inc.	-12.6%	0%	-52.22%	-34.25%	-53.36%	-44.59%

For the past year Nightstar Therapeutics plc has stronger performance than Checkpoint Therapeutics Inc.

Summary

Nightstar Therapeutics plc beats Checkpoint Therapeutics Inc. on 4 of the 7 factors.

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.